Orencia® Intravenous (abatacept)

Covers IV Orencia (abatacept) only for FDA‑approved uses—adult rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (≥2 years), adult psoriatic arthritis, and prophylaxis of acute aGVHD in HSCT recipients ≥2 years from matched or 1‑allele‑mismatched unrelated donors when given with a calcineurin inhibitor and methotrexate; off‑label uses are excluded. Approval requires indication‑specific age and specialist prescriber/consultation, documentation of required prior therapy or contraindications (e.g., 3‑month trial of a biologic or csDMARD for RA; prior agents or concurrent methotrexate/contraindication for JIA), verification of donor type and concomitant GVHD meds, weight/dosing limits including a 1000 mg maximum, and reauthorization after ≥6 months with documented clinical response.

"Orencia is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis."